newsfilter
← Latest News
Business Wire·

ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH

Pivekimab Triplet Demonstrates Encouraging CR, Composite CR, and MRD Negativity Rates; Broad Anti-Leukemia Activity Observed Across All Molecular Subsets Evaluated Pivekimab-Containing Triplet Well-Tolerated with